<DOC>
	<DOCNO>NCT03011528</DOCNO>
	<brief_summary>Ewing 's sarcoma relate tumour ( ESFT ) rare tumour , peak incidence second decade life . They start often bone , characterize specific translocation involve so-called EWS gene . In one patient three , stag procedure detect metastatic tumour diagnosis , commonly lung , bone , bone marrow . ESFT treatment strategy multidisciplinary , combine primary chemotherapy , local treatment , consolidation chemotherapy . The primary metastatic dissemination important prognostic factor , survival rate around 70-75 % localized tumour , contrast le 50 % patient primary metastatic disease . Among primary metastatic patient , bone involvement / bone marrow strike markedly prognosis patient . While long-term survival patient isolated pleural pulmonary metastasis approximately 50 % , whereas 0 25 % patient bone marrow involvement . In 1999 , Intergroup EURO EWING build new study protocol patient Ewing tumour . For patient primary extrapulmonary metastatic Ewing tumour ( R3 patient ) , protocol propose heavy induction chemotherapy , order propose consolidation high dose chemotherapy high rate patient . The high-dose Busulfan Melphalan chemotherapy ( BuMel ) base Busulfan ( 600 mg/m² ) Melphalan ( 140 mg/m² ) , autologous peripheral blood stem cell ( PBSC ) support . Of note , full population patient metastatic disease , 3-year EFS rate 27 % ( SD 3 % ) , OS rate 34 % ( SD 4 % ) , median follow-up 3.9 year diagnosis , median survival time 1.6 year .</brief_summary>
	<brief_title>First-line Treatment Ewing Tumours With Primary Extrapulmonary Dissemination Patients From 2 50 Years</brief_title>
	<detailed_description>Ewing 's sarcoma relate tumour ( ESFT ) rare tumour , peak incidence second decade life . They start often bone , characterize specific translocation involve so-called EWS gene . The gene rearrangement result production transcription factor , majority EWS-FLI1 transcription . In one patient three , stag procedure detect metastatic tumour diagnosis ; metastasis involve commonly lung , bone , bone marrow . Therefore , addition local imaging , initial extension assessment Ewing tumour include least chest CT scan , bone marrow extensive evaluation , comprise bone marrow puncture several different sector , bone marrow biopsy , bone image evaluation . The FDG-PET scan sensible bone scan conventional imaging MRI detection bone metastases . It widely use bone metastasis search Ewing tumour seem useful complement search extra-osseous metastasis ( outside lung ) , include bone marrow metastasis . The full-body MRI still evaluation disease extension evaluation . ESFT treatment strategy multidisciplinary , combine primary chemotherapy , local treatment , consolidation chemotherapy . The local treatment may combine surgery / radiotherapy , accord tumour site size , tumour response . ESFT chemotherapy base alkylating agent ( ifosfamide / cyclophosphamide ) , etoposide , anthracyclines , vincristine , actinomycin . The primary metastatic dissemination important prognostic factor , survival rate around 70-75 % localized tumour , contrast le 50 % patient primary metastatic disease . Among primary metastatic patient , bone involvement / bone marrow strike markedly prognosis patient . While long-term survival patient isolated pleural pulmonary metastasis approximately 50 % , whereas 0 25 % patient bone marrow involvement . In 1999 , Intergroup EURO EWING build new study protocol patient Ewing tumour , localize metastatic 50 year age . For patient primary extrapulmonary metastatic Ewing tumour ( R3 patient ) , protocol propose heavy induction chemotherapy , order propose consolidation high dose chemotherapy high rate patient . The high-dose BuMel chemotherapy base Busulfan ( 600 mg/m² ) Melphalan ( 140 mg/m² ) , autologous peripheral blood stem cell ( PBSC ) support . The study enrol 281 patient primary dissemination skeletal metastasis , without bone marrow involvement without additional pulmonary metastasis metastases site . In contrast distribution entire group patient Ewing tumour , primary site subgroup extremity 31 % patient , pelvis/abdomen 45 % , axial/other 24 % patient . The overall survival 3 year 28 % ( SD 4 % ) group primary tumour abdomen pelvis , versus 39 % ( SD 6 % ) two group . Of note , full population patient metastatic disease , 3-year EFS rate 27 % ( SD 3 % ) , OS rate 34 % ( SD 4 % ) , median follow-up 3.9 year diagnosis , median survival time 1.6 year .</detailed_description>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>1 . Ewing tumour histologically cytologically confirm , harbor specific transcript , extrapulmonary metastasis . 2 . Ewing tumour previously treat . 3 . Age 2 50 year . 4 . Measurable disease cross sectional imaging ( RECIST 1.1 ) evaluable disease functional metabolic , positron emission tomography scanner ( PET SCAN ) method ( e.g. , cytology/histology ) . 5 . General status compatible study treatment ( LANSKY score ≥ 50 % , Karnofsky ≥ 50 % , Eastern Cooperative Oncology Group ( ECOG ) ≤ 2 ) . 6 . Adequate bone marrow function ( applicable case bone marrow disease ) . Platelets ≥ 100 x 109 /L Absolute Neutrophil Count ( ANC ) ≥ 1 x 109 /L Hemoglobin ≥ 8g /dL . 7 . Adequate liver function : Aspartate Aminotransferase ( AST ) Alanine Transferase ( ALT ) ≤ 5 x Upper Limit Normal ( ULN ) Bilirubin conjugate fraction ( BCF ) ≤ 2 x Upper Limit Normal ( ULN ) 8 . No absolute contraindication BusulfanMelphalan radiotherapy primary tumour necessary . 9 . Adequate cardiac renal function : Creatinine &lt; 1.5 normal age clearance &gt; 60 ml/min/1.73 m² ; Left Ventricular Ejection Fraction ( LVEF ) &gt; 50 % and/or shorten fraction &gt; 28 % . 10 . No underlying disease contraindicate study treatment . 11 . Patient likely compliant recommend study medical monitoring treatment . 12 . Patients childbearing potential must agree use adequate contraception duration study treatment 12 month woman 6 month men follow completion therapy . 13 . Females childbearing potential must negative serum βhuman chorionic gonadotropin ( HCG ) pregnancy test within 10 day prior study inclusion , and/or urine pregnancy test within 48 hour first administration study treatment . 14 . Patients cover health insurance system . 15 . Patient , patient 's legal representative , inform sign informed consent . 1 . Age 2 great 50 year . 2 . Ewing tumour localize , solely pleural and/or lung metastasis . 3 . Primary tumour localize spine . 4 . Concomitant disease , particularly infectious disease , likely interfere patient 's treatment . 5 . History cancer , accord investigator 's judgment . 6 . Life expectancy &lt; 2 month . 7 . Patient already include another clinical trial investigational drug . 8 . Pregnant breastfeeding patient . 9 . Person deprive liberty guardianship . 10 . Patient likely unable comply study medical monitoring geographical , social psychological reason .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>